Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may outperform existing treatments from Apellis Pharmaceuticals and Astellas ...
Background: Previously we reported on the therapeutic monoclonal anti-human C2 antibody empasiprubart that inhibits activation of the classical and lectin pathways of complement. Preclinical studies ...
Introduction: Sepsis-associated encephalopathy (SAE) is characterized by acute neurological dysfunction and hippocampal damage, with oxidative stress being a key driver of neuronal injury. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results